Alejandra D. Martinez

El Palomar, B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Beyond Effectiveness: Impact of Cladribine on Patient-Reported Outcomes and Quality of Life in Latin American Populations With Multiple Sclerosis.

Beyond Effectiveness: Impact of Cladribine on Patient-Reported Outcomes and Quality of Life in Latin American Populations With Multiple Sclerosis.

Journal: Cureus

Published: December 08, 2025

Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.

Practical issues concerning the use of optical coherence tomography in multiple sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro Latam EM study group.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 29, 2025

Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.

Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.

Journal: Clinical neuropharmacology

Published: July 15, 2024

Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).

Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).

Journal: Multiple sclerosis and related disorders

Published: February 26, 2024

Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.

Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: January 22, 2024

Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.

Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.

Journal: Journal of the neurological sciences

Published: October 22, 2023

Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.

Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: September 27, 2022

Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.

Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.

Journal: Multiple sclerosis and related disorders

Published: July 27, 2022

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

Journal: Multiple sclerosis and related disorders

Published: May 26, 2022

Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.

Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: March 24, 2022

Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina.

Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina.

Journal: Multiple sclerosis and related disorders

Published: December 10, 2021

Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

Journal: Multiple sclerosis and related disorders

Published: October 09, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026